Cognition Therapeutics (CGTX) Projected to Release Earnings on Thursday

Cognition Therapeutics (NASDAQ:CGTX) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Cognition Therapeutics to post earnings of ($0.07) per share and revenue of $5.30 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. On average, analysts expect Cognition Therapeutics to post ($0.30) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.

Cognition Therapeutics Stock Performance

Shares of CGTX opened at $0.75 on Thursday. The stock has a fifty day moving average price of $0.92 and a two-hundred day moving average price of $1.08. Cognition Therapeutics has a 52-week low of $0.55 and a 52-week high of $1.83. The company has a market cap of $71.23 million, a price-to-earnings ratio of -4.41 and a beta of 1.80.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CGTX. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Monday, September 21st. Wall Street Zen cut Cognition Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of Cognition Therapeutics in a research report on Monday, October 5th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Cognition Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.33.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration.

Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.